Collectively, these findings delineate galectin-3 as a negative regulator of inflammation and macrophage invasion that opposes adverse atherosclerosis progression and confirms MMP12 as a potential target for medical intervention of atherosclerosis. This evidence concerns the gene LGALS3 and atherosclerosis.